PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Mian, A A; Rafiei, A; Haberbosch, I; Zeifman, A; Titov, I; Stroylov, V; Metodieva, A; Stroganov, O; Novikov, F; Brill, B; Chilov, G; Hoelzer, D; Ottmann, O G; Ruthardt, M

Mian, A A; Rafiei, A; Haberbosch, I; Zeifman, A; Titov, I; Stroylov, V; Metodieva, A; Stroganov, O; Novikov, F; Brill, B; Chilov, G; Hoelzer, D; Ottmann, O G; Ruthardt, M.

Afiliação

Mian AA; Department of Hematology, Goethe University, Frankfurt, Germany.
Rafiei A; Department of Hematology, Goethe University, Frankfurt, Germany.
Haberbosch I; Department of Hematology, Goethe University, Frankfurt, Germany.
Zeifman A; 1] Fusion Pharma, LLC, Moscow, Russian Federation [2] Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.
Titov I; 1] Fusion Pharma, LLC, Moscow, Russian Federation [2] Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.
Stroylov V; 1] Fusion Pharma, LLC, Moscow, Russian Federation [2] Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.
Metodieva A; Department of Hematology, Goethe University, Frankfurt, Germany.
Stroganov O; 1] Fusion Pharma, LLC, Moscow, Russian Federation [2] Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.
Novikov F; 1] Fusion Pharma, LLC, Moscow, Russian Federation [2] Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.
Brill B; Institute for Biomedical Research, Georg-Speyer-Haus, Frankfurt, Germany.
Chilov G; 1] Fusion Pharma, LLC, Moscow, Russian Federation [2] Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.
Hoelzer D; Department of Hematology, Goethe University, Frankfurt, Germany.
Ottmann OG; Department of Hematology, Goethe University, Frankfurt, Germany.
Ruthardt M; Department of Hematology, Goethe University, Frankfurt, Germany.

Leukemia ; 29(5): 1104-14, 2015 May.

Article em En | MEDLINE | ID: mdl-25394714

Assuntos

Antineoplásicos/farmacologia; Proteínas de Fusão bcr-abl/metabolismo; Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico; Leucemia Mielogênica Crônica BCR-ABL Positiva/genética; Mutação; Piridinas/farmacologia; Triazóis/farmacologia; Animais; Antígenos Ly/metabolismo; Apoptose; Linhagem Celular Tumoral; Proliferação de Células; Análise Mutacional de DNA; Feminino; Humanos; Imidazóis/farmacologia; Concentração Inibidora 50; Células K562; Proteínas de Membrana/metabolismo; Camundongos; Camundongos Endogâmicos C57BL; Modelos Moleculares; Mutagênese; Mutação Puntual; Proteínas Proto-Oncogênicas c-kit/metabolismo; Piridazinas/farmacologia; Translocação Genética; Ensaios Antitumorais Modelo de Xenoenxerto; Tirosina Quinase 3 Semelhante a fms/metabolismo

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Triazóis / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Mutação / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google